Cargando…
Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19
OBJECTIVES: COVID-19 pandemic seems to be under control. However, despite the vaccines, 5 to 10% of the patients with mild disease develop moderate to critical forms with potential lethal evolution. In addition to assess lung infection spread, chest CT helps to detect complications. Developing a pre...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667132/ https://www.ncbi.nlm.nih.gov/pubmed/37405504 http://dx.doi.org/10.1007/s00330-023-09759-x |
_version_ | 1785139184517775360 |
---|---|
author | Zysman, Maéva Asselineau, Julien Saut, Olivier Frison, Eric Oranger, Mathilde Maurac, Arnaud Charriot, Jeremy Achkir, Rkia Regueme, Sophie Klein, Emilie Bommart, Sébastien Bourdin, Arnaud Dournes, Gael Casteigt, Julien Blum, Alain Ferretti, Gilbert Degano, Bruno Thiébaut, Rodolphe Chabot, Francois Berger, Patrick Laurent, Francois Benlala, Ilyes |
author_facet | Zysman, Maéva Asselineau, Julien Saut, Olivier Frison, Eric Oranger, Mathilde Maurac, Arnaud Charriot, Jeremy Achkir, Rkia Regueme, Sophie Klein, Emilie Bommart, Sébastien Bourdin, Arnaud Dournes, Gael Casteigt, Julien Blum, Alain Ferretti, Gilbert Degano, Bruno Thiébaut, Rodolphe Chabot, Francois Berger, Patrick Laurent, Francois Benlala, Ilyes |
author_sort | Zysman, Maéva |
collection | PubMed |
description | OBJECTIVES: COVID-19 pandemic seems to be under control. However, despite the vaccines, 5 to 10% of the patients with mild disease develop moderate to critical forms with potential lethal evolution. In addition to assess lung infection spread, chest CT helps to detect complications. Developing a prediction model to identify at-risk patients of worsening from mild COVID-19 combining simple clinical and biological parameters with qualitative or quantitative data using CT would be relevant to organizing optimal patient management. METHODS: Four French hospitals were used for model training and internal validation. External validation was conducted in two independent hospitals. We used easy-to-obtain clinical (age, gender, smoking, symptoms’ onset, cardiovascular comorbidities, diabetes, chronic respiratory diseases, immunosuppression) and biological parameters (lymphocytes, CRP) with qualitative or quantitative data (including radiomics) from the initial CT in mild COVID-19 patients. RESULTS: Qualitative CT scan with clinical and biological parameters can predict which patients with an initial mild presentation would develop a moderate to critical form of COVID-19, with a c-index of 0.70 (95% CI 0.63; 0.77). CT scan quantification improved the performance of the prediction up to 0.73 (95% CI 0.67; 0.79) and radiomics up to 0.77 (95% CI 0.71; 0.83). Results were similar in both validation cohorts, considering CT scans with or without injection. CONCLUSION: Adding CT scan quantification or radiomics to simple clinical and biological parameters can better predict which patients with an initial mild COVID-19 would worsen than qualitative analyses alone. This tool could help to the fair use of healthcare resources and to screen patients for potential new drugs to prevent a pejorative evolution of COVID-19. CLINICAL TRIAL REGISTRATION: NCT04481620. CLINICAL RELEVANCE STATEMENT: CT scan quantification or radiomics analysis is superior to qualitative analysis, when used with simple clinical and biological parameters, to determine which patients with an initial mild presentation of COVID-19 would worsen to a moderate to critical form. KEY POINTS: • Qualitative CT scan analyses with simple clinical and biological parameters can predict which patients with an initial mild COVID-19 and respiratory symptoms would worsen with a c-index of 0.70. • Adding CT scan quantification improves the performance of the clinical prediction model to an AUC of 0.73. • Radiomics analyses slightly improve the performance of the model to a c-index of 0.77. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-023-09759-x. |
format | Online Article Text |
id | pubmed-10667132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-106671322023-07-05 Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19 Zysman, Maéva Asselineau, Julien Saut, Olivier Frison, Eric Oranger, Mathilde Maurac, Arnaud Charriot, Jeremy Achkir, Rkia Regueme, Sophie Klein, Emilie Bommart, Sébastien Bourdin, Arnaud Dournes, Gael Casteigt, Julien Blum, Alain Ferretti, Gilbert Degano, Bruno Thiébaut, Rodolphe Chabot, Francois Berger, Patrick Laurent, Francois Benlala, Ilyes Eur Radiol Computed Tomography OBJECTIVES: COVID-19 pandemic seems to be under control. However, despite the vaccines, 5 to 10% of the patients with mild disease develop moderate to critical forms with potential lethal evolution. In addition to assess lung infection spread, chest CT helps to detect complications. Developing a prediction model to identify at-risk patients of worsening from mild COVID-19 combining simple clinical and biological parameters with qualitative or quantitative data using CT would be relevant to organizing optimal patient management. METHODS: Four French hospitals were used for model training and internal validation. External validation was conducted in two independent hospitals. We used easy-to-obtain clinical (age, gender, smoking, symptoms’ onset, cardiovascular comorbidities, diabetes, chronic respiratory diseases, immunosuppression) and biological parameters (lymphocytes, CRP) with qualitative or quantitative data (including radiomics) from the initial CT in mild COVID-19 patients. RESULTS: Qualitative CT scan with clinical and biological parameters can predict which patients with an initial mild presentation would develop a moderate to critical form of COVID-19, with a c-index of 0.70 (95% CI 0.63; 0.77). CT scan quantification improved the performance of the prediction up to 0.73 (95% CI 0.67; 0.79) and radiomics up to 0.77 (95% CI 0.71; 0.83). Results were similar in both validation cohorts, considering CT scans with or without injection. CONCLUSION: Adding CT scan quantification or radiomics to simple clinical and biological parameters can better predict which patients with an initial mild COVID-19 would worsen than qualitative analyses alone. This tool could help to the fair use of healthcare resources and to screen patients for potential new drugs to prevent a pejorative evolution of COVID-19. CLINICAL TRIAL REGISTRATION: NCT04481620. CLINICAL RELEVANCE STATEMENT: CT scan quantification or radiomics analysis is superior to qualitative analysis, when used with simple clinical and biological parameters, to determine which patients with an initial mild presentation of COVID-19 would worsen to a moderate to critical form. KEY POINTS: • Qualitative CT scan analyses with simple clinical and biological parameters can predict which patients with an initial mild COVID-19 and respiratory symptoms would worsen with a c-index of 0.70. • Adding CT scan quantification improves the performance of the clinical prediction model to an AUC of 0.73. • Radiomics analyses slightly improve the performance of the model to a c-index of 0.77. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-023-09759-x. Springer Berlin Heidelberg 2023-07-05 2023 /pmc/articles/PMC10667132/ /pubmed/37405504 http://dx.doi.org/10.1007/s00330-023-09759-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Computed Tomography Zysman, Maéva Asselineau, Julien Saut, Olivier Frison, Eric Oranger, Mathilde Maurac, Arnaud Charriot, Jeremy Achkir, Rkia Regueme, Sophie Klein, Emilie Bommart, Sébastien Bourdin, Arnaud Dournes, Gael Casteigt, Julien Blum, Alain Ferretti, Gilbert Degano, Bruno Thiébaut, Rodolphe Chabot, Francois Berger, Patrick Laurent, Francois Benlala, Ilyes Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19 |
title | Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19 |
title_full | Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19 |
title_fullStr | Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19 |
title_full_unstemmed | Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19 |
title_short | Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19 |
title_sort | development and external validation of a prediction model for the transition from mild to moderate or severe form of covid-19 |
topic | Computed Tomography |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667132/ https://www.ncbi.nlm.nih.gov/pubmed/37405504 http://dx.doi.org/10.1007/s00330-023-09759-x |
work_keys_str_mv | AT zysmanmaeva developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT asselineaujulien developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT sautolivier developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT frisoneric developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT orangermathilde developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT mauracarnaud developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT charriotjeremy developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT achkirrkia developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT reguemesophie developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT kleinemilie developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT bommartsebastien developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT bourdinarnaud developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT dournesgael developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT casteigtjulien developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT blumalain developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT ferrettigilbert developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT deganobruno developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT thiebautrodolphe developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT chabotfrancois developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT bergerpatrick developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT laurentfrancois developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 AT benlalailyes developmentandexternalvalidationofapredictionmodelforthetransitionfrommildtomoderateorsevereformofcovid19 |